ABL1 and acute myeloid leukemia: However, only a few studies have evaluated the effect of TKI treatment before and after allo‐HCT, measurable residual disease (MRD) status, and additional cytogenetic abnormalities influencing transplant outcomes in patients with AML with BCR::ABL1.